Hospira hails ‘solid’ second quarter performance

Hospira has posted its financial results for the second quarter of the current fiscal year, reporting growth according to several financial measures.

The company’s net sales total for the quarter was $968.2 million (619.5 million pounds), a 1.2 per cent year-on-year increase, while income from operations and diluted earnings per share rose by 27.7 per cent and 206.3 per cent respectively.

Strong sales were noted in the firm’s specialty injectable pharmaceuticals division, thanks to the performance of individual products such as the sedation agent Precedex.

The firm also hailed the success of its Project Fuel optimisation initiatives, its improved standing in the acute-care proprietary pharmaceuticals sector and the recent launch of its second biosimilar product in Europe.

Christopher Begley, chairman and chief executive officer, said: “We are highly focused on executing our strategy of investing for growth and improving margins and cash flow, as well as on driving quality improvements across our global manufacturing organisation.”

Earlier this month, Hospira published data from a recent trial of its TheraDoc clinical surveillance system, demonstrating its effectiveness in monitoring and reducing rates of hospital infections.